Skip to main content
Submitted by PatientsEngage on 8 January 2020

What is the impact of maternal obesity and gestational diabetes on neonatal adiposity and childhood obesity? Dr. Giridhara R Babu, the lead investigator of the study from the Public Health Foundation of India, Bangalore, helps explain the key findings of this study.

In India alone, 4.3 million pregnant women are found to be overweight or obese. Obesity is a public health concern for pregnant women. Obesity leads to complications during pregnancy and birth, including a high rate of C-sections, preterm delivery, and even fetal death. Also, it is a risk factor for Gestational Diabetes Mellitus (GDM), macrosomia (larger than the average weight of baby), and childhood adiposity. Adiposity is defined as significant deposits of fat around skin folds in all areas of the body. Childhood adiposity is, in turn, a risk factor for adult-onset obesity, hypertension, Diabetes Mellitus, and Cardiovascular diseases. The association between these factors was the core of a recent study undertaken by the Public Health Foundation of India (PHFI), Bangalore.

Between the periods of 2016 to 2019, 1020 pregnant women (within 36 gestational weeks) visiting 3 public urban hospitals were enrolled for this study. The women were assessed using the Edinburgh Postnatal Depression Scale. At the same time, physical activity was measured through a validated questionnaire that checked on exercise, hobbies, household chores, sedentary, and other everyday daily operations of the participant. The women were followed up until a week after the birth of their baby when the baby's measurements were taken to assess for macrosomia.

Of the total participants, 9.7% of women were found to be obese, and 16.4% were diagnosed with GDM. Among the neonates born during the cohort, 14.6% had adiposity. On following up, women with obesity and GDM delivered a larger proportion of babies with large birth weight (18.3% vs. 9.1%), head and chest size, and skinfold thickness compared to women without obesity or GDM (the control group).

Dr. Giridhara R Babu, the lead investigator of the study from the Indian Institute of Public Health, Bangalore, helps explain the key findings of this study.

1.   Can you explain the independent effects of GDM and maternal obesity on neonatal adiposity?

The odds of having neonatal adiposity is 116% (twice) higher for children born to obese mothers (OR=2.16, 95% CI 1.46-3.18) as compared to mother. Similarly, the odds of having neonatal adiposity are 121% higher for children born to mothers with GDM compared to children born to non-GDM mothers, OR=2.21(95% CI1.38, 3.52). Independent effect means that GDM and maternal obesity, without the presence of each other, can result in adiposity in newborns in India.

2.   Why has the role of maternal obesity and GDM not been studied in low and middle-income countries before?

Consideration of maternal obesity as an adverse risk factor during pregnancy has been less studied so far in low- and middle-income countries (LMICs). Few studies are examining the role of GDM; however, these studies focused either one of the burdens. The interaction between these two risk factors, especially the mediation role of GDM is not studied. In India, there is a greater focus on controlling anemia and undernutrition in women. The prevalence of obesity and diabetes are increasing in LMICs, such as India. As a result, the LMICs are burdened with the dual burden of undernutrition and overweight. Nearly 50% of pregnant women in India attend public hospitals and antenatal services. The women attending public hospitals are generally from the lower or middle class. As such, they were thought to be afflicted with undernutrition, and therefore, addressing obesity, and GDM screening in this population is not considered as a priority in LMICs. Our study informs the policy and public alike in prioritizing and addressing both these risks during antenatal period.

3.   Does age of mother affect her chances of getting GDM? If so, can you explain how and why that is so?

There are high chances of being diagnosed with GDM as the age of the mother increases due to physiological variations. In our study, the age of the mother had a significant effect on the chances of being diagnosed with GDM. As age advances, the chances of being diagnosed with GDM are higher. However, the mean age of women with GDM in our cohort is 25.4 years, suggests that women attending public hospitals are affected at a relatively younger age.

As maternal age increases, the incidence of GDM can be due to declining ß – cell function.

(1) Carbohydrate intolerance can develop as a part of the aging process. This may be the consequence of insulin resistance caused by a post-receptor defect resulting in a reduced rate of peripheral glucose disposal. (1) Glucose tolerance is determined by a balance between insulin secretion and insulin action, and this deteriorates with age. Insulin resistance that develops with age may also be a consequence of increased adiposity.

4.   As per your study, how did obesity affect the baby compared to GDM?

Our results strongly suggest that both maternal obesity and GDM are independently associated with adiposity in neonates. GDM is a stronger determinant of adiposity in neonates and mediates the effect of maternal obesity on neonatal adiposity.

5.   In your opinion, why do multiparous women (bearing more than one child) have a higher incidence of obesity (70.7%) and GDM (63.5%)?

Parity and obesity are positively associated, as parity increases the odds of having obesity increases. It may be due to long-term weight gain, higher pre-pregnancy BMI, increase in age and physical inactivity.

6.   How do you propose India to achieve universal screening for GDM?

Public hospitals cater to more than 50% of pregnant women and require a quick, reliable point of care diagnostic tests. As of now, the non-fasting criteria as the Glucose Challenge Test (GCT) can be considered as a superior choice over OGTT. However, this needs to be validated in the selected population. Women with high-risk factors like obesity and increased age, previous GDM history, family history of Diabetes Mellitus, history of stillbirth, abortion, macrosomia can be screened in the first trimester. Rest of the women who do not present any risk factors can be screened in the second trimester. Also, awareness regarding GDM must be created among healthcare professionals and pregnant women alike. Therefore, strict adherence to the screening and management guidelines of GDM by the Government of India should be followed by all the health care facilities in all the states. Training aspects should focus on considering these in a training module for the health care providers.

References:

1. “Acta Diabetologia”; Volume 41, November 4, Page(s); 154 – 157

Condition
Changed
Sat, 01/11/2020 - 19:39

Stories

  • 7 reasons to love Chia Seeds. Plus 3 simple recipes.
    By nutritionist Kohila Govindaraju What are Chia Seeds ? They are a member of the mint family Why love them? • Chia seeds improve insulin sensitivity and glucose tolerance. The soluble fibre in the seeds helps to stabilise blood glucose levels. When soaked in liquid, they develop a gelatinous texture. This gel formation phenomenon creates the barrier between carbohydrates and digestive enzymes that ultimately slow down the conversion of carbohydrates into simple sugar.…
  • Malays, Indians with Type 2 diabetes more likely to suffer strokes, heart attacks: Study
    SINGAPORE: In a decade-long diabetes study, researchers from Khoo Teck Puat Hospital (KTPH) found that among those with Type 2 Diabetes Mellitus (T2DM), Malays and Indians are at higher risk of cardiovascular diseases compared to Chinese patients. Malay patients had two times higher risk while Indians had 1.7 times higher risk of diseases such as heart attacks and strokes, compared to Chinese patients with T2DM, according to findings of a study released by the healthcare cluster that manages…
  • Diabetes has kept me healthy
    SR Madhu, 73, has had diabetes for 23 years, and has avoided the health hazards faced by his peers. He thanks the diabetes lifestyle for his wellbeing. Plus, his experience of hypoglycaemia.  I was quite upset to discover in 1991 that diabetes had hit me. I had been "on the borderline" of diabetes for a few years whenever I had been tested in India. But when I crossed the international border in 1991 to take up a UN assignment in Zimbabwe, the diabetes crossed…
  • FDA Approval For Two-In-One Diabetes Pill XIGDUO™ XR
    U.S. Food and Drug Administration has approved once-daily XIGDUO™ XR (dapagliflozin and metformin hydrochloride extended-release) for the treatment of adults with type 2 diabetes. It is already approved in Australia XIGDUO XR combines two anti-hyperglycemic agents with complementary mechanisms of action, dapagliflozin (trade name in the U.S. FARXIGA™), an inhibitor of sodium-glucose cotransporter 2 (SGLT2), and metformin hydrochloride (HCl) extended-release, a biguanide, in a once-daily oral…
  • Giant leap in Type 1 Diabetes treatment
    Harvard stem cell researchers today announced that they have made a giant leap forward in the quest to find a truly effective treatment for type 1 diabetes, a condition that affects an estimated 3 million Americans at a cost of about $15 billion annually. With human embryonic stem cells as a starting point, the scientists are for the first time able to produce, in the kind of massive quantities needed for cell transplantation and pharmaceutical purposes, human insulin-producing…
  • Diabetes patient jabbing themselves with insulin
    Worried About Insulin Shots?
    Persons with diabetes often get extremely stressed when their doctor wants to move them from pills to insulin shots. Dr Shital Patel allays the fears and explains what to expect and how to go about it. The transition from pills to insulin injections can be a worrying experience for many Diabetes Type 2 patients. You should know that this does not mean that your diabetes has worsened or that your Type 2 diabetes has changed to Type 1. You are being prescribed insulin because after…
  • FDA approves Trulicity a weekly injectable to treat type 2 diabetes
    The U.S. FDA today approved Trulicity (dulaglutide), a once-weekly subcutaneous injection to improve glycemic control (blood sugar levels), along with diet and exercise, in adults with type 2 diabetes. "Type 2 diabetes is a serious chronic condition that causes blood glucose levels to rise higher than normal,” said Mary Parks, M.D., deputy director of the Office of Drug Evaluation II in the FDA’s Center for Drug Evaluation and Research. “Trulicity is a new treatment option, which can be used…
  • Artificial sweeteners may promote diabetes, claim scientists
    Artificial sweeteners may contribute to soaring levels of diabetes, according to a controversial study that suggests the additives could exacerbate the problem they are meant to tackle. Researchers in Israel found that artificial sweeteners used in diet drinks and other foods can disrupt healthy microbes that live in the gut, leading to higher blood sugar levels – an early sign of diabetes. But the study has left many experts unconvinced. The findings draw largely on tests of just one sweetener…
  • A woman holding up the pregnancy test kit
    Pre-conception care for a healthy pregnancy
    Planning a pregnancy? Obstetrician and gynaecologist Dr Chandan Dubey tells you what you need to do before you conceive. A woman’s good health prior to and during pregnancy is vital for optimal outcomes for her and the baby. You should consult a general physician or gynaecologist for preconception care and counselling. In the meantime, here’s what you should be aware of:  Lose weight (if you are overweight): Obesity is a serious problem in pregnancy. It increases the…
  • FDA approves weight-management drug Contrave
    The U.S. Food and Drug Administration today approved Contrave (naltrexone hydrochloride and bupropion hydrochloride extended-release tablets) as treatment option for chronic weight management in addition to a reduced-calorie diet and physical activity. The drug is approved for use in adults with a body mass index (BMI) of 30 or greater (obesity) or adults with a BMI of 27 or greater (overweight) who have at least one weight-related condition such as high blood pressure (hypertension), type 2…